Journal
ANNALES D ENDOCRINOLOGIE
Volume 79, Issue 5, Pages 583-590Publisher
MASSON EDITEUR
DOI: 10.1016/j.ando.2018.07.010
Keywords
Diabetes; Dyslipidemia; mTOR inhibitors
Categories
Ask authors/readers for more resources
Using mTOR inhibitors (mTORi) as anticancer drugs led to hyperglycemia (12-50%) and hyperlipidemia (7-73%) in phase-III trials. These high rates require adapted treatment in cancer patients. Before initiating mTORi treatment, lipid profile screening should be systematic, with fasting glucose assay in non-diabetic patients and HbA(1C) in diabetic patients. After initiation, lipid profile monitoring should be systematic, with fasting glucose assay in non-diabetic patients, every 2 weeks for the first month and then monthly. The HbA(1C) target is <= 8%, before and after treatment initiation in known diabetic patients and in case of onset of diabetes under mTORi. LDL-cholesterol targets should be adapted to general health status and cardiovascular and oncologic prognosis. If treatment is indicated, pravastatin should be prescribed in first line; atorvastatin and simvastatin are contraindicated. Fenofibrate should be prescribed for hypertriglyceridemia > 5 g/l resisting dietary measures adapted to oncologic status. In non-controllable hypertriglyceridemia exceeding 10 g/l, mTORi treatment should be interrupted and specialist opinion should be sought. (C) 2018 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available